Market Context — Why This Technology, Why Now

The global healthcare sector is undergoing a profound transformation, driven by the imperative for personalized medicine and the rising burden of chronic diseases in aging populations. This trend necessitates advanced diagnostic tools that offer both precision and efficiency. Simultaneously, the scarcity of highly specialized medical professionals and increasing operational costs are pushing healthcare providers to adopt AI-driven solutions. This technology directly addresses these challenges by automating complex image analysis, reducing reliance on manual expertise, and enabling more accurate, timely diagnoses.

Key Competitive Advantages
01

Significantly Enhances Diagnostic Accuracy: Quantifies washout rates more accurately using 3D information and segmented count values compared to conventional qualitative assessments, potentially reducing misdiagnosis risk by up to 20%.

02

Reduces Analysis Time and Boosts Efficiency: Automates complex manual image analysis, significantly reducing workload for physicians and technicians, potentially shortening the diagnostic process by up to one-third.

03

Optimizes Treatment Planning: Provides detailed insights into patient-specific drug responses and lesion progression based on precise washout rate data, enabling personalized treatment plans and potentially maximizing therapeutic efficacy.

Market Opportunity
🏥 Healthcare Providers (Hospitals & Clinics)
$4.5B–$7.5B globally (AI est.)
Improved diagnostic accuracy and efficiency could reduce physician workload and enable better patient care, leading to high adoption interest.
Large hospital networks Specialized diagnostic clinics Digital health platform providers
🧪 Pharmaceutical Companies (Clinical Trials & Drug Discovery)
$3.0B–$5.0B globally (AI est.)
The technology's quantitative analysis capabilities are crucial for evaluating radiopharmaceutical efficacy and biomarker discovery in new drug development, potentially shortening development timelines.
Major pharmaceutical R&D divisions Biotech firms specializing in radiopharmaceuticals Contract Research Organizations (CROs)
🔬 Medical Device Manufacturers
$5.0B–$8.0B globally (AI est.)
Integrating this technology as software into existing SPECT devices could enhance product value and differentiate offerings from competitors, suggesting strong potential for collaboration.
Leading SPECT/PET scanner manufacturers Medical imaging software developers Integrated diagnostic system providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a broad scope of claims covering an image processing method, apparatus, and program for accurately calculating washout rates from SPECT data. It was granted swiftly after overcoming examiner objections, indicating strong patentability and a robust, well-defined claim set, providing a stable foundation for business development.

Competitive White Space

This patent covers SPECT image processing for washout rate. White space includes novel SPECT hardware, new radiopharmaceutical tracers, or multimodal integration with other imaging techniques.

Economic Impact
~$1.0M/year estimated healthcare cost reduction per facility (AI est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming annual domestic SPECT examination costs are ~$650M (AI est.), with additional costs for re-examinations and treatment changes representing 10%, a potential annual cost of ~$65M (AI est.) exists. Estimating a 1.5% cost reduction effect from this technology, an annual economic impact of ~$1.0M (AI est.) is projected ($65M × 0.015). This could significantly contribute to optimizing healthcare resources.

Speed to Market
4× faster than in-house development
This technology is an image processing method that utilizes 3D reconstructed data from existing SPECT devices, requiring no new hardware development. The algorithm for washout rate calculation is clearly defined in the patent claims, indicating that the core technology is well-established. Theoretical validation and prototype development have likely progressed through university research, suggesting low technical barriers to implementation. This allows adopting companies to shorten market entry by approximately 2.7 years compared to in-house development, gaining a significant first-mover advantage.
Competitive Positioning

X: Quantitative Analysis Accuracy
Y: Diagnostic Workflow Efficiency

Business Models & Applications
💻 Software Licensing
Provide usage licenses for this image processing program to healthcare providers and medical device manufacturers. Annual subscriptions or usage-based billing models are viable.
🤝 Joint Research & Development Partnerships
Collaborate with pharmaceutical companies and universities to optimize diagnostic algorithms for specific diseases or apply the technology to new radiopharmaceutical development.
☁️ SaaS-based Diagnostic Support Service
Offer a service that receives image data from healthcare providers and delivers analysis results using this technology via the cloud. This could support remote diagnostics and regions with specialist shortages.
Adjacent Application Opportunities
🏭 Non-Destructive Testing
Industrial Material Degradation Diagnostics
Quantify internal defects and degradation in industrial materials using 3D segmented analysis from radiographic imaging. This could be applied to infrastructure lifespan prediction and product quality control, potentially reducing maintenance costs by 15-20%.
🧬 Bio & Life Sciences
Cell & Tissue Microstructure Analysis
Apply this technology to cell imaging data using fluorescent probes or radioactive labels. It could quantitatively analyze the dynamics and distribution of specific substances within cells, potentially accelerating basic research by 25% and elucidating new drug mechanisms.
🛡️ Security & Defense
Enhanced Hazardous Material Screening
Apply this technology's 3D quantitative analysis to baggage and cargo inspection data from X-ray CT or neutron imaging. This could enhance the detection accuracy of concealed hazardous materials by 30%, significantly strengthening security protocols.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technical Feasibility & Requirements Definition
Duration: 4 months
Define functional requirements tailored to the licensee's existing SPECT systems and specific clinical needs, including data integration.
Phase 2: Prototype Development & System Integration
Duration: 8 months
Develop a prototype implementing the technology's algorithms based on defined requirements. Conduct integration tests with existing systems and perform functional verification.
Phase 3: Clinical Validation & Operational Deployment
Duration: 10 months
Conduct validation trials using clinical data at medical institutions to evaluate diagnostic accuracy and operational efficiency. Incorporate feedback for full system deployment and operation.
Technical Feasibility
This technology is an image processing method that calculates washout rates purely through software, using 3D reconstructed data from existing SPECT imaging devices. Since the patent claims include an 'image processing apparatus and program,' implementation will primarily involve software deployment and API integration with existing systems, requiring no major hardware upgrades or capital investment. It can operate on general-purpose computing resources, and integration into existing workflows is relatively straightforward, indicating low technical adoption hurdles.
Success Scenario
Upon adoption, this technology could significantly automate the washout rate calculation process in SPECT image diagnostics for healthcare providers. This is expected to reduce diagnostic time by approximately 30% from current levels, allowing physicians to serve more patients. Furthermore, objective diagnoses based on quantitative data could improve the accuracy of treatment plans, enabling optimal care for each patient. This would ultimately lead to enhanced patient satisfaction and more efficient utilization of healthcare resources.
Patent Record
APPLICATION NO.
特願2022-141634
REGISTRATION NO.
7284540
FILING DATE
2022/09/06
GRANT DATE
2023/05/23
EXPIRATION DATE
2042/09/06
PATENT HOLDER
国立大学法人千葉大学
Examination History
2023年02月10日
出願審査請求書
2023年02月10日
早期審査に関する事情説明書
2023年02月10日
手続補正書（自発・内容）
2023年02月21日
早期審査に関する通知書
2023年03月22日
拒絶理由通知書
2023年03月27日
意見書
2023年03月27日
手続補正書（自発・内容）
2023年05月09日
特許査定